# Agenus

Source: https://onco.cc/companies/agenus/  
OnCo record `agenus` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Agenus is a Massachusetts immuno-oncology company developing botensilimab, an Fc-enhanced anti-CTLA-4 antibody, with its anti-PD-1 balstilimab, notably in microsatellite-stable colorectal cancer where checkpoint inhibitors have not worked.

## Summary

Agenus, based in Lexington, Massachusetts and listed on Nasdaq, develops checkpoint antibodies and cancer vaccines. Its lead combination is botensilimab, a next-generation anti-CTLA-4 antibody with an engineered Fc region, given with balstilimab, an anti-PD-1 antibody, which has shown responses in microsatellite-stable colorectal cancer without liver metastases and other cold tumours; the company has sought accelerated approval and runs registrational trials. OnCo records it as a registry sponsor of phase 3 cancer trials.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Also known as: Agenus Inc.; Agenus Inc
- Tags: ctgov-sponsor
- HQ: Lexington, MA
- Type: biotech
- Website: https://agenusbio.com

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Agenus
- Official website: https://agenusbio.com
- ClinicalTrials.gov: trials led by Agenus: https://clinicaltrials.gov/search?lead=Agenus
- Wikipedia: https://en.wikipedia.org/wiki/Agenus

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/)
- fronts: [Immunotherapy](https://onco.cc/fronts/immunotherapy/)
- targets: [CTLA-4](https://onco.cc/targets/ctla4/), [PD-1](https://onco.cc/targets/pd1/)
- drugs: [Balstilimab](https://onco.cc/drugs/balstilimab/), [Botensilimab](https://onco.cc/drugs/botensilimab/), [Ivermectin](https://onco.cc/drugs/ivermectin/), [Zalifrelimab](https://onco.cc/drugs/zalifrelimab/)
- trials: [A Study of Botensilimab and Balstilimab for Colorectal Cancer With ctDNA+ After Surgery and Chemotherapy](https://onco.cc/trials/nct07227636/), [A Study of Botensilimab and Balstilimab for Rectal Adenocarcinoma](https://onco.cc/trials/nct06843434/), [A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer](https://onco.cc/trials/nct05608044/), [A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab](https://onco.cc/trials/nct06782555/), [Ivermectin with balstilimab or pembrolizumab in metastatic triple-negative breast cancer (Cedars-Sinai phase 1/2)](https://onco.cc/trials/nct05318469/), [Platform Study of Immunotherapy Combinations in Colorectal Cancer Liver Metastases](https://onco.cc/trials/nct06300463/), [RECTIFY-1: Neoadjuvant Botensilimab + Balstilimab in MSS/pMMR Early Rectal Cancer](https://onco.cc/trials/nct07735624/), [Vorbipiprant (CR6086) / Balstilimab (AGEN2034) Combination in Stage IV Refractory pMMR - MSS CRC, and Other Metastatic GI Cancers](https://onco.cc/trials/nct05205330/)
- key papers: [Botensilimab plus balstilimab in relapsed/refractory microsatellite stable metastatic colorectal cancer: a phase 1 trial](https://onco.cc/key-papers/paper-bullock-botensilimab-balstilimab-mss-colorectal-nat-med-2024/)
- ideas: [Select microsatellite stable patients for immunotherapy by a measured immune biomarker, not by how many treatments they have already failed](https://onco.cc/ideas/idea-crc-mss-immunotherapy-by-biomarker-not-by-line/)

---
JSON: https://onco.cc/api/v1/entities/agenus.json